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Background: It is increasingly being recognized that the elimination of HCV requires a multidisciplinary approach
and effective cooperation between primary and secondary care.
Objectives: As part of a project (HepCare Europe) to integrate primary and secondary care for patients at risk of
or infected with HCV, we developed a multidisciplinary educational Masterclass series for healthcare professio-
nals (HCPs) working in primary care in Dublin and Bucharest. This article aims to describe and evaluate the series
and examine how this model might be implemented into practice.
Methods: GPs and other HCPs working in primary care, addiction treatment services and NGOs were invited to
eight 1 day symposia (HCV Masterclass series), examining the burden and management of HCV in key popula-
tions. Peer-support sessions were also conducted, to give people affected by HCV and community-based organi-
zations working with those directly affected, an update on the latest developments in HCV treatment.
Results: One hundred percent of participants ‘strongly agreed’ or ‘agreed’ that the Masterclass helped them to
appreciate the role of integrated services in ‘the management of patients with HCV’. One hundred percent of
participants indicated the importance of a ‘designated nurse to liaise with hospital services’. An improvement of
knowledge regarding HCV management of patients with high-risk behaviour was registered at the end of
the course.
Conclusions: Integrated approaches to healthcare and improving the knowledge of HCPs and patients of the
latest developments in HCV treatment are very important strategies that can enhance the HCV care pathway
and treatment outcomes.
Introduction
Addressing the challenge of developing new models of integrated
care for HCV requires effective cooperation between primary and
secondary care involving multidisciplinary approaches to care. The
HepCare Europe project1 is an EU-supported service innovation
project and feasibility study at four European sites (Dublin, London,
Seville and Bucharest) to develop, implement and evaluate inter-
ventions to enhance identification and treatment of HCV among
key populations [people who inject drugs (PWID), the homeless
and prisoners].
A large number of healthcare professionals (HCPs) and social
care professionals (SCPs) have a key role to play in the treatment
pathway for hepatitis C. Therefore, education of the patient as well
as HCPs and community service provider organizations working
with those at risk of acquiring hepatitis C is extremely important in
order to optimize treatment outcomes. Previous studies identified
that educating patients about HCV increased their knowledge of
HCV, increased screening rates, increased treatment uptake,2
reduced infection-related risk behaviour3 and promoted access to
care.4 Therefore, linking them to an appropriate and efficient
multidisciplinary team can enhance HCV patient care.
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Shared decision making within a multidisciplinary team is a vital
component of effective hepatitis C treatment. The proportion of
PWID who accept referral to weekly HCV peer-support groups to
be assessed for HCV is higher than the proportion of those accept-
ing hospital-based referral for HCV clinical care, underlining the
positive effect the presence of a multidisciplinary team has, as
they integrate general health, addiction and HCV treatment in
an available, acceptable and predictable manner.5 The current lit-
erature highlights the use of group activities, didactic lectures,
workshops, case studies, demonstrations and small group discus-
sions as well as other instructional and activity-based methods
when educating HCPs around the world in integrative, cooperative
healthcare.6 The duration of different symposiums, their frequency
and the variation of techniques utilized depend on a variety of
factors, such as the respective topic, the target professionals and
the clinical domains.7
By educating all HCPs and SCPs playing a key role in the hepatitis
C care pathway, the success of multidisciplinary care for hepatitis
C would expand beyond addressing the narrow scope of the
virological disease alone, to incorporate the bigger picture of any
accompanying common and complex health issues that may
have been overlooked, such as pain, asthma, substance use disor-
ders (including alcohol), mental health issues, cardiac conditions,
rheumatological conditions and others. By distributing resources
and increasing the competency and role of primary care and other
healthcare/non-healthcare professionals, more patients would be
able to access treatment while minimizing the pressure placed on
scarce speciality care.8
Hence, as part of the HepCare project to integrate primary and
secondary care for patients at risk of or infected with HCV, we
developed a series of educational symposia at the Dublin and
Bucharest sites, aimed at HCPs and community service provider
organizations involved in the hepatitis C care pathway. This article
aims to evaluate a series of educational symposia that examined
how to integrate treatment of HCV in primary and secondary care
and to identify how this model might be achieved in practice. We
describe participants’ appraisal of the Masterclasses and their
feedback on implementing a multidisciplinary approach to the
treatment of hepatitis C.
Methods
Ethics
The study was approved by the Mater Misericordiae University Hospital
Research Ethics Committee in Dublin (1/378/1722) and the Victor Babes
Clinical Hospital for Infectious and Tropical Diseases Research Ethics in
Bucharest (3/06.01.2016).
Study design and setting
From local general practices, NGOs and addiction treatment services, GPs/
other HCPs working in primary care were invited to eight HCV symposia
(HCV Masterclass series) in Dublin, Ireland, and Bucharest, Romania, to
examine the burden of HCV and how to optimize HCV care. In Bucharest
HCPs from three opioid substitution therapy (OST) centres, two high-secur-
ity prisons, two night shelters and two NGOs, and GPs working in districts
from Bucharest with a high burden of vulnerable people were invited. In
Dublin invitations to attend the HCV Masterclasses were sent to all HCPs (in-
fectious disease consultants, GPs, pharmacists, nurses, community service
providers) and organizations involved in the HCV care pathway in the Dublin
area. The delivery method included a series of short PowerPoint presenta-
tions delivered by a multidisciplinary range of healthcare professionals
(Appendices E and F, available as Supplementary data at JAC Online).
Information on how to prevent new infections, why/how to screen, new
approaches to diagnosis and treatment as well as treating coexisting prob-
lem alcohol use were addressed. In Bucharest the presentations were
focused mainly on the complex problems of people who inject drugs, peo-
ple using new psychoactive drugs and on HIV/HCV-coinfected patients. In
Dublin, PowerPoint presentations were delivered by a range of HCPs
involved in the HCV care pathway (infectious disease consultants, GPs,
pharmacists, nurses, community service providers). Each presenter chose
the content for their presentation based on how best to inform the audi-
ence of their role and priorities in an integrated HCV care pathway.
Attendees received no funds for attending and the pharmaceutical industry
was not involved in the organization of HCV Masterclasses.
Key outcomes were analysed across the Masterclass series, including
the effectiveness of the method of delivery, the usefulness of the
Masterclass symposium and the usefulness of the support provided by the
HepCare Europe programme when implemented into practice.
Data collection
Dublin
Each Masterclass was delivered to all participants and evaluation occurred
immediately post-session. Following each symposium, a questionnaire was
distributed among the participants, who were asked to rate, using a five-
point Likert scale (where 4=strongly agree, 0=strongly disagree), how use-
ful the Masterclass had been, the effectiveness of information delivery and
how the programme could best be implemented in practice (Appendix A).
Participants were also asked to rate, using a four-point Likert scale (where
4=very useful, 0=not at all useful), how useful they thought the support
provided by the HepCare Europe programme would be when implemented
in their practice/organization (Appendix A). Finally, participants were asked
an open-ended question about what other support/activity would help
them manage patients with HCV and also asked to provide ‘any other com-
ments’ relating to the Masterclass (Appendix A). Seven peer-support educa-
tional sessions were also conducted in Dublin to give people affected by
HCV and community-based organizations working with those directly
affected an update on the latest developments in HCV treatment.
Bucharest
In Bucharest, as well as the Masterclass questionnaire (Appendix B), a pre/
post Masterclass evaluation instrument (Appendices C and D) was used to
measure participants’ general knowledge about HCV management in key
populations in Bucharest. This allowed an evaluation of the improvement
of participants’ knowledge of current HCV care as a result of the
Masterclass. The post-intervention questionnaire also asked for partici-
pants’ views about the usefulness of the session and the implementation
of a multidisciplinary approach to HCV management.
In addition to the Masterclass series, 11 peer-support sessions were
also conducted for patients from key populations in Bucharest (home-
less people and PWID) as training day programmes. The participants
received flyers and a booklet, containing information about modes of
HCV acquisition, HCV diagnosis, prevention methods and treatment
with direct-acting antivirals (DAAs). They also had the opportunity to
ask questions, to learn from the experience of peers and to share their
fears and social problems.
The written materials were also distributed in waiting rooms of
GPs/primary care facilities, in emergency rooms of hospitals and, with
the help of social workers, to individuals who inject drugs who were
living on the streets. The booklets were distributed to peers, social
workers from NGOs, psychologists and other HCPs involved in HCV
management.
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Analysis
The percentage of participants choosing a particular item on the Likert scale
was calculated for each Masterclass. Content analysis of responses to
open-ended questions was conducted; similar responses were grouped
and numbers of participants were counted for each group.
Results
Over 200 participants involved in HCV care in the community from
participating countries attended the Masterclass series. The results
show the variation in percentage scores on an item across the
Masterclass series.
Dublin (see Table 1 for summary of responses)
The most highly rated outcome was that the Masterclass helped
participants ‘appreciate the role of primary care’ and ‘secondary
care’ in the ‘management of patients with HCV’ (100% of partici-
pants ‘strongly agreed’ or ‘agreed’). Ninety-seven to 100 percent
of participants ‘strongly agreed’ or ‘agreed’ they were better able
to ‘describe new approaches to assessment (FibroScan)’ and ‘new
approaches to treatment’ (88%–96%) of patients with HCV. In re-
gard to making an integrated model of care happen in practice,
100% of participants acknowledged the importance of a ‘desig-
nated nurse to liaise with hospital services’. Some expanded on
this topic in the open question section, saying it would be ‘vital’ as
nurse liaison would be able to ‘join the dots’ of a patient’s treat-
ment and ‘ease communication’. Participants thought that that
‘educational programmes’ (91%–100%) and ‘computerized-deci-
sion making’ (88%–92%) would be ‘useful’ or ‘very useful’ support
in their everyday management of hepatitis C.
However, despite positive appraisal of the Masterclass symposi-
ums, some participants commented on a need to ‘link up with
health’, gain ‘feedback from teams’ and receive ‘letters of progress’
on ‘treatment plans’, all of which point to a need to enhance com-
munication between HCPs.
Bucharest (see Table 2 for summary of responses)
Almost all participants reported that the main reason for
attending the Masterclass was to improve their knowledge
about HCV management in patients with high-risk behaviour, as
they were not satisfied with their current level of knowledge
about this subject.
At the end of the sessions 95%–100% of HCPs agreed that the
Masterclass improved their knowledge on the impact of alcohol on
Table 1. Summary of responses from Masterclasses (Dublin)
Category
Strongly
disagree Disagree Neither Agree
Strongly
agree
Total number
of responses
As a result of the seminar, I am better able to:
Appreciate the role of primary care in the management of
patients with HCV
0% 0% 0% 62% 38% 58
Appreciate the role of secondary care in the management of
patients with HCV
0% 0% 0% 57% 43% 58
Describe new approaches to assessment for patients with
HCV
(e.g. FibroScan)
0% 0% 5% 48% 47% 58
Describe new approaches to treatment for patients with HCV 0% 0% 14% 52% 34% 58
Understand the importance of integrating services to better
treat patients
0% 0% 2% 58% 40% 58
Understand that patients have multiple co- morbidities 0% 0% 0% 32% 68% 58
Better understand complications of untreated HCV infection 0% 15% 30% 35% 20% 57
Interact with the Mater Hospital Infectious Diseases
Department
0% 0% 20% 40% 40% 56
The following were useful in helping me achieve these outcomes:
Presentations 0% 0% 5% 60% 35% 54
Support
Not at all useful Somewhat
useful
Useful Very useful Total number
of responses
In implementing the new ‘HepCare’ programme in your practice, how useful would you find the following supports?
Audit and feedback 0% 19% 56% 25% 48
Educational programmes 0% 0% 71% 29% 49
Computerized decision-making support 0% 12% 41% 47% 48
A designated nurse to liaise with hospital services 0% 0% 11% 89% 52
Academic detailing (i.e. practice visits by team) 0% 6% 18% 76% 46
108 participants attended three Masterclasses; 58 participants completed evaluation forms.
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the clinical evolution of HCV, the increasing prevalence of HCV
among prisoners, the difficulties in the management of HIV/HCV/
TB-coinfected patients and the extrahepatic manifestations of HCV.
They were also informed about the social and disease barriers faced
by Bucharest patients in order to access DAA treatment and they
acknowledged the importance of a multidisciplinary approach to
the management of HCV in patients with high-risk behaviour.
A high percentage (90%–95%) agreed that a mobile team re-
sponsible for HCV screening and linkage to care for patients from
key populations would be very useful for better management of
HCV. In addition, they also considered that peer-support sessions
and informative materials and booklets for patients are very useful
in order to improve adherence to treatment and the follow-up
process.
The pre/post evaluations revealed an improvement in the
knowledge of HCPs regarding the prevalence of HCV among PWID
in Bucharest, modes of HCV acquisition, extrahepatic manifesta-
tions, DAA treatment and drug–drug interactions (up from 42.5%
to 97%). More than half of the participants agreed that the social
conditions of the patients and their addiction and comorbidities, as
well as the high costs of the DAA treatment and poor involvement
of local authorities, are important barriers and challenges for HCPs
in HCV management and for patients to access adequate medical
services (Table 3 and Figure 1).
Table 2. Summary of responses from Masterclasses (Bucharest)
Category
Strongly
disagree Disagree Neither Agree
Strongly
agree
As a result of the seminar, I am better able to:
Understand the impact of alcohol use in clinical evolution of hepatitis C (HCV) 0% 0% 0% 2% 98%
Describe why alcohol use is an important issue among problem drug users 0% 0% 2% 73% 25%
Approach the conversation about alcohol with patients 0% 0% 1% 37% 62%
Understand the high burden of HIV/HCV coinfection among prisoners 0% 0% 0% 23% 77%
Understand the importance of HIV/HCV/TB coinfection treatment among
prisoners
0% 0% 0% 15% 85%
Appreciate the complex management of HIV/HCV/TB coinfected injecting drug
users
0% 0% 3% 33% 64%
Understand the new approaches regarding HCV treatment 0% 0% 0% 37% 73%
Describe the ‘treatment as prevention’ method regarding HCV treatment for
patients from vulnerable groups
0% 0% 0% 10% 90%
Describe the barriers patients from vulnerable groups have to face in order to
access healthcare services
0% 0% 0% 12% 88%
Appreciate the difficulties faced by injecting drug users in the process of social
reintegration
0% 0% 2% 5% 93%
Appreciate the importance of integration of primary and secondary care for
HCV management
0% 0% 0% 3% 97%
Improve my collaboration with medical staff from Victor Babes Hospital 0% 0% 0% 6% 94%
The following were useful in helping me achieve these outcomes:
Presentations 0% 0% 0% 3% 97%
Workshops 0% 0% 0% 5% 95%
Support
Not at all useful Somewhat
useful
Useful Very useful
In implementing the new ‘Hepcare’ programme in your practice, how useful would you find the following supports?
Educational programmes 0% 0% 4% 96%
A designated trained person to liaise with hospital services 0% 0% 10% 90%
Academic detailing (i.e. practice visits by team) 0% 0% 20% 80%
Peer support meetings for patients 0% 0% 7% 93%
Informational materials for patients 0% 0% 4% 96%
Contact with mobile teams responsible for HCV screening among vulnerable
patients
0% 0% 4% 96%
Would any other support/activity help you manage patients with HCV? 0% 0% 8% 92%
Any other comments?
The total number of participants was 143; the total number of respondents was 105.
When asked ‘Please give a brief appreciation of the seminar, scoring the following aspects from 1 (min) to 5 (max):’, the responses were: Importance
of the information for daily practice, 5; Agenda of the seminar, 5; Support materials, 5; Interaction between the lecturers and the attendees, 5;
Perspectives for collaboration between GPs and medical staff from the hospital for a better management of patients from vulnerable groups, 4.
When asked whether the participants would recommend the course to a colleague, 97% answered ‘Strongly agree’ and 3% ‘Agree’.
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Discussion
Key findings
The Hepcare Europe Masterclass Symposium series highlights the
benefits of educational seminars as a way of delivering current
best practice in the treatment of hepatitis C to a multidisciplinary
audience in an efficient and cost-effective way.
In Bucharest, the pre-skills assessment and post-skills assess-
ment showed an improvement in knowledge of HCV care related
to HCV modes of transmission, drug use and HCV/DAA treatment,
as well as extrahepatic manifestations of HCV and HCV prevalence
among patients with high-risk behaviours. Almost all participants
concluded that socio-economic conditions and poor involvement
of local authorities are the main barriers to treatment and under-
lined the importance of a multidisciplinary approach. Owing to the
cumulative efforts of the HepCare team and other physicians
involved in HCV management, structural barriers (disease and la-
boratory) to HCV treatment were removed in Romania in
September 2018.
In Dublin 100% of participants ‘strongly agreed’ or ‘agreed’
that the Masterclass helped them ‘appreciate the role of
primary care’ and ‘secondary care’ in the ‘management of
patients with HCV’. In regard to making an integrated model of
care happen in practice, 100% of participants acknowledged
the importance of a ‘designated nurse to liaise with hospital
services’.
Comparison with existing literature
The feedback from the Masterclass series highlights the need for
multidisciplinary cooperation in optimizing HCV care. Data from
the literature indicate the success of multidisciplinary models in
enhancing treatment outcomes in the field of diabetes,9 HIV/HCV
comorbidiy10 and oncology.11 The pivotal role of a liaison nurse in
the HCV cascade of care was highlighted in the feedback forms
from the Masterclasses, and this is supported in previous research
outlining the central role of liaison nurses in HCV treatment to en-
hance patient access to treatment, and improve adherence rates
to treatment.12 Furthermore, research evaluating the effective-
ness of a nurse model in caring for prison inmates with HCV wit-
nessed a 69% sustained virological response rate amongst
prisoners on treatment.13
Table 3. Summary of the results of the pre- and post-course knowledge evaluation tests for HCV Masterclasses, Bucharest
Masterclass 1 (n=54) Masterclass 2 (n=51)
Topic pre-course post-course pre-course post-course
Prevalence of HCV among PWID in Romania 33 (61.1) 52 (96.2) 34 (70.8) 48 (94.1)
Modes of HCV acquisition 23 (42.5) 48 (88.9) 24 (47.0) 48 (94.1)
HCV extrahepatic manifestations 23 (42.5) 45 (83.3) 21 (41.1) 43 (84.3)
DAA treatment 27 (50.0) 49 (90.7) 23 (45.1) 49 (96.0)
Drug–drug interactions 27 (50.0) 47 (87.0) 24 (47.0) 46 (90.1)
Influence of injectable psychoactive drugs on HCV transmission 33 (61.1) 52 (96.2) 30 (58.9) 49 (96.0)
Injecting drug use and DAA treatment 25 (46.3) 53 (98.1) 29 (56.9) 50 (98.0)
Results shown are n (%).
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Figure 1. Results of the pre and post evaluation questionnaires used in HCPs who attended the HCV Masterclass in Bucharest.
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The findings associated with the Masterclass series are consist-
ent with current literature, underlining how the use of didactic
video, presentations, discussions and workshops have great poten-
tial in educating HCPs, improving knowledge and enhancing col-
laboration.11,14,15 Research indicates that a key barrier to the
implementation of a variety of medical educational interventions
is a lack of time;16 in contrast, however, the engagement with edu-
cational sessions tends to be more positive.17 The educational ses-
sions were concise and brief, with the aim of delivering a
maximum amount of relevant, up-to-date information within a
minimum time, increasing acceptability and accessibility of the
seminar for professionals.
Research suggests that cost-effectiveness, efficiency and opti-
mal delivery of educational seminars to HCPs and SCPs can be fur-
ther developed by the use of webinars to amalgamate information
on an electronic platform that is accessible to medical students
and professionals.15,18 As such, based on the feedback from the
Masterclass series in Dublin, an online educational webinar was
developed aimed at enhancing a multidisciplinary approach to
hepatitis C treatment (available at http://www.ucd.ie/medicine/
hepcare/oureducation/resources/).
The Bucharest team also created a video containing the most
important messages from their Masterclass presentations, the
activities performed by mobile teams, as well as the printed educa-
tional materials for both patients and HCPs involved in HCV man-
agement (available at http://www.spitalulbabes.ro/hepcare-
europe-video-heped-d-6-1/).
Strengths and limitations
The strength of this study is that it highlights the benefits of
educational seminars as a way of enhancing knowledge of
current best practice in HCV care to a multidisciplinary audience
of HCPs and patients in an efficient and cost-effective way.
However, the study is also limited in several ways. The findings
cannot be generalized over a large group of different HCPs
involved in hepatitis C treatment. A formal invitation was sent
out to the participants but non-attendance rates were not
measured, hence, only ‘enthusiasts’ were likely to have been
recruited and participated in the educational symposiums.
Furthermore, owing to time constraints a pre-Masterclass skills
evaluation did not take place in Ireland, and this should be
included in future Masterclasses. Finally, to date no follow-up
data have been collected as to whether attendees have put
what they learned into practice.
Conclusions
In both Dublin and Bucharest, where DAAs became recently
available, there are still important challenges to overcome to
ensure patients adhere to treatment pathways right through to
elimination of their HCV. Therefore, treatment of HCV needs
to incorporate more than just medication; it requires a more
holistic approach and recognition of existing barriers such as
housing, social support, mental health issues, alcohol and sub-
stance use and incarceration.19 This underlines the importance
of integrated care that makes use of an efficient and coopera-
tive multidisciplinary team in order to optimize care in the
community.
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